MECOM and acute myeloid leukemia: Overall 84% of patients in the AML cohort had one or more poor-risk cytogenetic or molecular feature, including 34% with a TP53 mutation and 13% with a MECOM rearrangement, two of the genomic features that are associated with the worst outcomes in AML [35, 36].